Cargando…
PFKFB4 facilitates palbociclib resistance in oestrogen receptor‐positive breast cancer by enhancing stemness
BACKGROUND: ER(+) breast cancer (ER(+) BC) is the most common subtype of BC. Recently, CDK4/6 inhibitors combined with aromatase inhibitors have been approved by FDA as the first‐line therapy for patients with ER(+) BC, and showed promising therapeutic efficacy in clinical treatment. However, resist...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816941/ https://www.ncbi.nlm.nih.gov/pubmed/36127291 http://dx.doi.org/10.1111/cpr.13337 |